Skip to content
OpenCapital
Get started

Achieve Life Sciences ACHV D&A

D&A at other companies

Pfizer logo
PfizerPFE
$1.61B-0.3%
Sionna Therapeutics, Inc. Common Stock logo
Sionna Therapeutics, Inc. Common StockSION
$154K-3.1%

Other financials

Income statement

See full
Net income-$10.2M+20.7%
EPS (diluted)-$0.19+48.6%

Balance sheet

See full
Cash & equivalents$28.1M+116%
Total debt$5.6M+332%
Total equity$10.7M+3.9%
Total assets$33.1M+21.0%

Cash flow

See full
Operating cash flow-$6.9M+37.5%
CapEx$750.0—
Free cash flow-$12.4M—

Valuation

See full
Market cap$585.16M+404%
Enterprise value$562.71M+439%

Returns & leverage

See full
Return on equity-496.1%-906pp
Debt / equity0.5×+0.4×
Current ratio2.6×-0.9×

Where this comes from

Reported directly by Achieve Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Achieve Life Sciences's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Achieve Life Sciences's D&A?
Achieve Life Sciences (ACHV) reported D&A of $57K in Q1 2026.
How has Achieve Life Sciences's D&A changed year-over-year?
Achieve Life Sciences's D&A decreased by 8.1% year-over-year, from $62K to $57K.
What is the long-term trend for Achieve Life Sciences's D&A?
Over 4 years (2021 to 2025), Achieve Life Sciences's D&A has grown at a -2.3% compound annual growth rate (CAGR), from $250K to $228K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.